Drug Profile
Zetomipzomib - Kezar Life Sciences
Alternative Names: KZR-616Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Onyx Pharmaceuticals
- Developer Everest Medicines; Kezar Life Sciences
- Class Anti-inflammatories; Antianaemics; Antirheumatics; Cyclopentanes; Hepatoprotectants; Morpholines; Small molecules; Urologics
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Autoimmune hepatitis; Dermatomyositis; Lupus nephritis; Polymyositis; Systemic lupus erythematosus
- Preclinical Haemophagocytic lymphohistiocytosis
- No development reported Autoimmune disorders
Most Recent Events
- 26 Feb 2024 NMPA approves IND application for zetomipzomib in Lupus nephritis
- 26 Feb 2024 Everest Medicines and Kezar Life Sciences plans a phase IIb PALIZADE trial for Lupus nephritis in China
- 03 Dec 2023 China National Medical Products Administration (NMPA) accepts IND for zetomipzomib for Autoimmune disorders including Lupus nephritis for review